{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:33:25Z","timestamp":1783492405062,"version":"3.55.0"},"reference-count":189,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["13,14"],"award-info":[{"award-number":["13,14"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmmc-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.yjmcc.2025.03.007","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:08:34Z","timestamp":1741781314000},"page":"102-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Advances in incretin therapies for targeting cardiovascular disease in diabetes"],"prefix":"10.1016","volume":"202","author":[{"given":"Timothy D.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana S.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Wootten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles J.","family":"De Blasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca H.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0005","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/CIRCULATIONAHA.111.087213","article-title":"Energy balance and obesity","volume":"126","author":"Hill","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0010","series-title":"Rang & Dale\u2019s Pharmacology [Internet]","first-page":"422","article-title":"Obesity","author":"Ritter","year":"2018"},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0015","series-title":"WHO European Regional Obesity Report 2022 [Internet]","first-page":"206","author":"World Health Organization","year":"2022"},{"issue":"10431","key":"10.1016\/j.yjmcc.2025.03.007_bb0020","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","author":"Phelps","year":"2024","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.yjmcc.2025.03.007_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2022-009773","article-title":"Economic impacts of overweight and obesity: current and future estimates for 161 countries","volume":"7","author":"Okunogbe","year":"2022","journal-title":"BMJ Glob. Health"},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0030","article-title":"The crucial role and mechanism of insulin resistance in metabolic disease","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"10085","key":"10.1016\/j.yjmcc.2025.03.007_bb0035","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","article-title":"Type 2 diabetes","volume":"389","author":"Chatterjee","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.yjmcc.2025.03.007_bb0040","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4239\/wjd.v5.i4.444","article-title":"Type 2 diabetes and cardiovascular disease: have all risk factors the same strength?","volume":"5","author":"Mart\u00edn-Tim\u00f3n","year":"2014","journal-title":"World J. Diabetes"},{"issue":"19","key":"10.1016\/j.yjmcc.2025.03.007_bb0045","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease: the Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.yjmcc.2025.03.007_bb0050","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.amepre.2023.05.011","article-title":"Sex differences in cardiovascular risk associated with prediabetes and undiagnosed diabetes","volume":"65","author":"Yoshida","year":"2023","journal-title":"Am. J. Prev. Med."},{"issue":"13","key":"10.1016\/j.yjmcc.2025.03.007_bb0055","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/eurheartj\/ehz914","article-title":"Type 2 diabetes-related sex differences in cardiovascular risk: reasons, ramifications, and clinical realities","volume":"41","author":"Sattar","year":"2020","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.yjmcc.2025.03.007_bb0060","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011295","article-title":"Diabetes mellitus\u2013related all-cause and cardiovascular mortality in a national cohort of adults","volume":"8","author":"Raghavan","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"7","key":"10.1016\/j.yjmcc.2025.03.007_bb0065","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.yjmcc.2025.03.007_bb0070","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2337\/diacare.27.8.1879","article-title":"The incidence of congestive heart failure in type 2 diabetes: an update","volume":"27","author":"Nichols","year":"2004","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.yjmcc.2025.03.007_bb0075","doi-asserted-by":"crossref","first-page":"277.e1","DOI":"10.1016\/j.ahj.2007.05.001","article-title":"Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF)","volume":"154","author":"Greenberg","year":"2007","journal-title":"Am. Heart J."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0080","series-title":"StatPearls [Internet]","article-title":"Left ventricular hypertrophy","author":"Bornstein","year":"2023"},{"issue":"11","key":"10.1016\/j.yjmcc.2025.03.007_bb0085","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic mechanisms of diabetic heart disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.yjmcc.2025.03.007_bb0090","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3390\/biomedicines12040765","article-title":"Diabetic cardiomyopathy\u2014from basics through diagnosis to treatment","volume":"12","author":"Radzioch","year":"2024","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.yjmcc.2025.03.007_bb0095","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.yjmcc.2025.03.007_bb0100","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/cvr\/cvac049","article-title":"Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy","volume":"119","author":"Phang","year":"2023","journal-title":"Cardiovasc. Res."},{"issue":"3","key":"10.1016\/j.yjmcc.2025.03.007_bb0105","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/bph.12943","article-title":"Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes","volume":"172","author":"Tate","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.yjmcc.2025.03.007_bb0110","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1042\/CS20160491","article-title":"Are targeted therapies for diabetic cardiomyopathy on the horizon?","volume":"131","author":"Tate","year":"2017","journal-title":"Clin. Sci."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0002-9149(91)90716-X","article-title":"Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham heart study)","volume":"68","author":"Galderisi","year":"1991","journal-title":"Am. J. Cardiol."},{"issue":"8","key":"10.1016\/j.yjmcc.2025.03.007_bb0120","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00592-021-01705-x","article-title":"Evidence for human diabetic cardiomyopathy","volume":"58","author":"Marfella","year":"2021","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.661297","article-title":"Sex differences of the diabetic heart","volume":"12","author":"Fourny","year":"2021","journal-title":"Front. Physiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2025.03.007_bb0130","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199307223290428","article-title":"Inclusion of women in clinical trials \u2013 policies for population subgroups","volume":"329","author":"Bennett","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0135","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1552-6909.1998.tb02594.x","article-title":"Inclusion of women in clinical trials: a historical overview of scientific ethical and legal issues","volume":"27","author":"Merkatz","year":"1998","journal-title":"J. Obstet. Gynecol. Neonatal. Nurs."},{"issue":"3","key":"10.1016\/j.yjmcc.2025.03.007_bb0140","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.neubiorev.2010.07.002","article-title":"Sex Bias in neuroscience and biomedical research","volume":"35","author":"Beery","year":"2010","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0145","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cobeha.2018.06.016","article-title":"Inclusion of females does not increase variability in rodent research studies","volume":"23","author":"Beery","year":"2018","journal-title":"Curr. Opin. Behav. Sci."},{"issue":"7500","key":"10.1016\/j.yjmcc.2025.03.007_bb0150","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/509282a","article-title":"Policy: NIH to balance sex in cell and animal studies","volume":"509","author":"Clayton","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0155","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/eurheartj\/ehv598","article-title":"Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes","volume":"37","author":"The EUGenMed","year":"2016","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.yjmcc.2025.03.007_bb0160","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2337\/db22-0192","article-title":"Sex differences in adipose tissue distribution determine susceptibility to Neuroinflammation in mice with dietary obesity","volume":"72","author":"Stranahan","year":"2022","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0165","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/EC-18-0450","article-title":"Sex hormones, obesity and type 2 diabetes: is there a link?","volume":"8","author":"Gambineri","year":"2018","journal-title":"Endocr. Connect."},{"issue":"5","key":"10.1016\/j.yjmcc.2025.03.007_bb0170","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1210\/en.2008-0971","article-title":"Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice","volume":"150","author":"Riant","year":"2009","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.yjmcc.2025.03.007_bb0175","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1210\/er.2012-1055","article-title":"The role of estrogens in control of energy balance and glucose homeostasis","volume":"34","author":"Mauvais-Jarvis","year":"2013","journal-title":"Endocr. Rev."},{"issue":"7","key":"10.1016\/j.yjmcc.2025.03.007_bb0180","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00394-011-0266-4","article-title":"Estrogen modulates abdominal adiposity and protects female mice from obesity and impaired glucose tolerance","volume":"51","author":"Stubbins","year":"2012","journal-title":"Eur. J. Nutr."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-138-1-200301070-00005","article-title":"Glycemic effects of postmenopausal hormone therapy: the heart and estrogen\/progestin replacement study: a randomized, double-blind, placebo-controlled trial","volume":"138","author":"Kanaya","year":"2003","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.yjmcc.2025.03.007_bb0190","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2337\/dc18-2388","article-title":"Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: eight-year data from a registry study","volume":"42","author":"Yassin","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0195","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13293-016-0059-9","article-title":"Sex and estrogens alter the action of glucagon-like peptide-1 on reward","volume":"7","author":"Richard","year":"2016","journal-title":"Biol. Sex Differ."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.678055","article-title":"The interplay of glucagon-like Peptide-1 receptor trafficking and signalling in pancreatic beta cells","volume":"12","author":"Marzook","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"9","key":"10.1016\/j.yjmcc.2025.03.007_bb0205","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1210\/clinem\/dgad176","article-title":"Disparities in the glycemic and incretin responses to Intraduodenal glucose infusion between healthy Young men and women","volume":"108","author":"Xie","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.yjmcc.2025.03.007_bb0210","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.2337\/db14-1751","article-title":"GLP-1 response to Oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO study","volume":"64","author":"F\u00e6rch","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0215","series-title":"StatPearls","article-title":"Behavioral approaches to obesity treatment","author":"Yearwood","year":"2024"},{"issue":"5","key":"10.1016\/j.yjmcc.2025.03.007_bb0220","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3810\/pgm.2013.09.2692","article-title":"Treatment of the obese patient in primary care: targeting and meeting goals and expectations","volume":"125","author":"Bray","year":"2013","journal-title":"Postgrad. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.yjmcc.2025.03.007_bb0225","first-page":"S1","article-title":"New vistas for the treatment of obesity: turning the tide against the leading cause of morbidity and cardiovascular mortality in the developed world","volume":"15","author":"Lepor","year":"2014","journal-title":"Rev. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0230","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12325-018-0824-8","article-title":"Body weight considerations in the Management of Type 2 diabetes","volume":"36","author":"Apovian","year":"2019","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.yjmcc.2025.03.007_bb0235","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/life13041012","article-title":"A comprehensive review on weight loss associated with anti-diabetic medications","volume":"13","author":"Haddad","year":"2023","journal-title":"Life"},{"issue":"11","key":"10.1016\/j.yjmcc.2025.03.007_bb0240","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.2337\/diacare.26.11.2983","article-title":"Use of Thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study","volume":"26","author":"Delea","year":"2003","journal-title":"Diab. Care"},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0245","article-title":"Implications of removing Rosiglitazone\u2019s black box warning and restricted access program on the uptake of Thiazolidinediones and dipeptidyl Peptidase-4 inhibitors among patients with type 2 diabetes","volume":"25","author":"Hickson","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0250","series-title":"StatPearls","article-title":"Metformin","author":"Corcoran","year":"2023"},{"issue":"9","key":"10.1016\/j.yjmcc.2025.03.007_bb0255","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.yjmcc.2025.03.007_bb0260","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.cmet.2010.04.001","article-title":"Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation","volume":"11","author":"Hawley","year":"2010","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.yjmcc.2025.03.007_bb0265","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nm.3787","article-title":"Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats","volume":"21","author":"Duca","year":"2015","journal-title":"Nat. Med."},{"issue":"7436","key":"10.1016\/j.yjmcc.2025.03.007_bb0270","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nature11808","article-title":"Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP","volume":"494","author":"Miller","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0275","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ihj.2017.05.009","article-title":"Metformin in heart failure patients","volume":"70","author":"Kinsara","year":"2018","journal-title":"Indian Heart J."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0280","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12882-022-02781-z","article-title":"A patient with severe metformin-associated lactic acidosis complicated by acute coronary syndrome: a case report","volume":"23","author":"Mammadova","year":"2022","journal-title":"BMC Nephrol."},{"issue":"39","key":"10.1016\/j.yjmcc.2025.03.007_bb0285","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.yjmcc.2025.03.007_bb0290","first-page":"796","article-title":"Metformina e insulina nell\u2019insufficienza cardiaca cronica: controindicazioni non controindicate e indicazioni non indicate","volume":"12","author":"Cosmi","year":"2011","journal-title":"G. Ital. Cardiol."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0295","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12933-020-01100-w","article-title":"Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis","volume":"19","author":"Halabi","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"issue":"8","key":"10.1016\/j.yjmcc.2025.03.007_bb0300","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.2337\/diabetes.52.8.2049","article-title":"Insulin constitutively secreted by beta-cells is necessary for glucose-stimulated insulin secretion","volume":"52","author":"Srivastava","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0305","series-title":"The Structure and Metabolism of the Pancreatic Islets","first-page":"181","article-title":"Evidence for different modes of insulin secretion","author":"Creutzfeldt","year":"1970"},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0310","series-title":"StatPearls","article-title":"Human insulin","author":"Dave","year":"2023"},{"issue":"5","key":"10.1016\/j.yjmcc.2025.03.007_bb0315","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ejhf.1146","article-title":"Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes","volume":"20","author":"Cosmi","year":"2018","journal-title":"Eur. J. Heart Fail."},{"issue":"6","key":"10.1016\/j.yjmcc.2025.03.007_bb0320","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134920","article-title":"Insulin receptor substrates differentially exacerbate insulin-mediated left ventricular remodeling","volume":"5","author":"Riehle","year":"2020","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0325","doi-asserted-by":"crossref","first-page":"E130","DOI":"10.1152\/ajpendo.00158.2021","article-title":"Insulin signaling in the heart","volume":"321","author":"Abel","year":"2021","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0330","series-title":"StatPearls","article-title":"Sodium-glucose transport protein 2 (SGLT2) inhibitors","author":"Padda","year":"2023"},{"issue":"3","key":"10.1016\/j.yjmcc.2025.03.007_bb0335","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.yjmcc.2025.03.007_bb0340","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes. Metab."},{"issue":"10","key":"10.1016\/j.yjmcc.2025.03.007_bb0345","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.yjmcc.2025.03.007_bb0350","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S2213-8587(15)00424-6","article-title":"Understanding EMPA-REG OUTCOME","volume":"3","author":"Muskiet","year":"2015","journal-title":"Lancet Diab. Endocrinol."},{"issue":"18","key":"10.1016\/j.yjmcc.2025.03.007_bb0355","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.yjmcc.2025.03.007_bb0360","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","article-title":"Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis","volume":"12","author":"Usman","year":"2024","journal-title":"Lancet Diab. Endocrinol."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0365","article-title":"Sex differences in risk of cardiovascular events and mortality with sodium glucose co-transporter-2 inhibitors versus glucagon-like peptide 1 receptor agonists in Australians with type 2 diabetes: a population-based cohort study","volume":"33","author":"Sharma","year":"2023","journal-title":"Lancet Reg. Health"},{"issue":"3","key":"10.1016\/j.yjmcc.2025.03.007_bb0370","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dsx.2020.02.012","article-title":"Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0375","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.cardfail.2023.10.320","article-title":"Sglt2 inhibitors in women and cardiovascular outcomes - Meta-analysis of sex differences in eleven randomized clinical trials","volume":"30","author":"Shah","year":"2024","journal-title":"J. Card. Fail."},{"issue":"5","key":"10.1016\/j.yjmcc.2025.03.007_bb0380","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.amjcard.2007.05.022","article-title":"Effect of glucagon-like Peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting","volume":"100","author":"Sokos","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0385","series-title":"Comprehensive Medicinal Chemistry III [Internet]","first-page":"481","article-title":"7.12 - GLP-1 receptor agonists for the treatment of diabetes and obesity","author":"Palani","year":"2017"},{"issue":"1133","key":"10.1016\/j.yjmcc.2025.03.007_bb0390","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/postgradmedj-2019-137186","article-title":"An overview of GLP-1 agonists and recent cardiovascular outcomes trials","volume":"96","author":"Sheahan","year":"2020","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2018.00584","article-title":"Dissecting the physiology and pathophysiology of glucagon-like Peptide-1","volume":"9","author":"Paternoster","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0400","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1042\/BST20120236","article-title":"Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function","volume":"41","author":"Koole","year":"2013","journal-title":"Biochem. Soc. Trans."},{"issue":"6","key":"10.1016\/j.yjmcc.2025.03.007_bb0405","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.yjmcc.2025.03.007_bb0410","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1530\/eje.0.1460863","article-title":"The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects","volume":"146","author":"Hui","year":"2002","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"10.1016\/j.yjmcc.2025.03.007_bb0415","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-like peptide 1 receptor agonists for type 2 diabetes","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diab. Spectr."},{"issue":"4","key":"10.1016\/j.yjmcc.2025.03.007_bb0420","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2337\/db08-1193","article-title":"GLP-1R agonist Liraglutide activates Cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice","volume":"58","author":"Noyan-Ashraf","year":"2009","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.yjmcc.2025.03.007_bb0425","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/cvr\/cvs123","article-title":"GLP-1 and cardioprotection: from bench to bedside","volume":"94","author":"Ravassa","year":"2012","journal-title":"Cardiovasc. Res."},{"issue":"10","key":"10.1016\/j.yjmcc.2025.03.007_bb0430","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.2215\/CJN.18771220","article-title":"GLP-1 receptor agonists in diabetic kidney disease","volume":"16","author":"Michos","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0435","article-title":"Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist\u2013based therapies","author":"Morissette","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.yjmcc.2025.03.007_bb0440","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101641","article-title":"Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction","volume":"66","author":"McLean","year":"2022","journal-title":"Mol. Metab."},{"issue":"4","key":"10.1016\/j.yjmcc.2025.03.007_bb0450","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1210\/en.2018-00004","article-title":"GLP-1 receptor expression within the human heart","volume":"159","author":"Baggio","year":"2018","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.yjmcc.2025.03.007_bb0455","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm.3128","article-title":"GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure","volume":"19","author":"Kim","year":"2013","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0460","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1479-5876-11-84","article-title":"Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies","volume":"11","author":"Wohlfart","year":"2013","journal-title":"J. Transl. Med."},{"issue":"18","key":"10.1016\/j.yjmcc.2025.03.007_bb0465","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.yjmcc.2025.03.007_bb0470","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1055\/s-0028-1082326","article-title":"The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance","volume":"40","author":"Nystr\u00f6m","year":"2008","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0475","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.738848","article-title":"Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system","volume":"12","author":"Puglisi","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.yjmcc.2025.03.007_bb0480","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4103\/2230-8210.152739","article-title":"Triple fixed drug combinations in type 2 diabetes","volume":"19","author":"John","year":"2015","journal-title":"Indian J. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.yjmcc.2025.03.007_bb0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032412","article-title":"Medication adherence in type 2 diabetes: the ENTRED study 2007, a French population-based study","volume":"7","author":"Tiv","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0490","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/DMSO.S351982","article-title":"The emerging role of dual GLP-1 and GIP receptor agonists in glycemic management and cardiovascular risk reduction","volume":"15","author":"Rizvi","year":"2022","journal-title":"Diab. Metab. Syndr. Obes."},{"issue":"26","key":"10.1016\/j.yjmcc.2025.03.007_bb0495","doi-asserted-by":"crossref","first-page":"19650","DOI":"10.1016\/S0021-9258(19)36565-2","article-title":"Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells","volume":"268","author":"G\u00f6ke","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"30","key":"10.1016\/j.yjmcc.2025.03.007_bb0500","doi-asserted-by":"crossref","first-page":"21432","DOI":"10.1016\/S0021-9258(19)36628-1","article-title":"Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4","volume":"267","author":"Raufman","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/j.yjmcc.2025.03.007_bb0505","doi-asserted-by":"crossref","first-page":"8641","DOI":"10.1073\/pnas.89.18.8641","article-title":"Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1","volume":"89","author":"Thorens","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.yjmcc.2025.03.007_bb0510","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.2337\/diabetes.48.5.1026","article-title":"Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (Ob\/Ob, db\/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)","volume":"48","author":"Young","year":"1999","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.yjmcc.2025.03.007_bb0515","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/endo.136.8.7628397","article-title":"Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV","volume":"136","author":"Kieffer","year":"1995","journal-title":"Endocrinology"},{"issue":"8","key":"10.1016\/j.yjmcc.2025.03.007_bb0520","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann. Intern. Med."},{"issue":"20","key":"10.1016\/j.yjmcc.2025.03.007_bb0525","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1161\/CIRCULATIONAHA.119.041659","article-title":"Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure\u2013related outcomes","volume":"140","author":"Fudim","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.yjmcc.2025.03.007_bb0530","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrd3148","article-title":"Liraglutide","volume":"9","author":"Drucker","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.yjmcc.2025.03.007_bb0535","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00125-001-0719-z","article-title":"The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men","volume":"45","author":"Agers\u00f8","year":"2002","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.yjmcc.2025.03.007_bb0540","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like Peptide-1 with pharmacokinetic properties suitable for once daily administration","volume":"43","author":"Knudsen","year":"2000","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.yjmcc.2025.03.007_bb0545","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1021\/jm070861j","article-title":"Structure\u2212activity and protraction relationship of long-acting glucagon-like Peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness","volume":"50","author":"Madsen","year":"2007","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.yjmcc.2025.03.007_bb0550","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3390\/ph3030764","article-title":"Liraglutide therapy for type 2 diabetes: overcoming unmet needs","volume":"3","author":"Sj\u00f6holm","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0555","series-title":"Diabetes","first-page":"A164","article-title":"The molecular basis for the delayed absorption of the once-daily human GLP-1 analoge, liraglutide","author":"Steensgaard","year":"2008"},{"issue":"11","key":"10.1016\/j.yjmcc.2025.03.007_bb0560","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1124\/dmd.110.034066","article-title":"Metabolism and excretion of the once-daily human glucagon-like Peptide-1 analog Liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase","volume":"38","author":"Malm-Erjef\u00e4lt","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.yjmcc.2025.03.007_bb0565","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126003","article-title":"Liraglutide improves pancreatic Beta cell mass and function in Alloxan-induced diabetic mice","volume":"10","author":"Tamura","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.yjmcc.2025.03.007_bb0570","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of Liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.yjmcc.2025.03.007_bb0575","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0580","article-title":"Diastolic cardiac function improvement by Liraglutide is mainly body weight reduction dependent but independently contributes to B-type natriuretic peptide reduction in patients with type 2 diabetes with preserved ejection fraction","volume":"2021","author":"Yagi","year":"2021","journal-title":"J. Diabetes Res."},{"issue":"25","key":"10.1016\/j.yjmcc.2025.03.007_bb0585","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/CIRCULATIONAHA.118.034516","article-title":"Effects of Liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke","volume":"138","author":"Verma","year":"2018","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.yjmcc.2025.03.007_bb0590","doi-asserted-by":"crossref","first-page":"423","DOI":"10.7326\/M18-1569","article-title":"Effect of Liraglutide on cardiovascular outcomes in elderly patients: a post hoc analysis of a randomized controlled trial","volume":"170","author":"Gilbert","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.yjmcc.2025.03.007_bb0595","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40265-014-0228-2","article-title":"Albiglutide: First Global Approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0600","unstructured":"D-H. Han. Update regarding Tanzeum injection availability [Internet], Medical Professionals Reference (2018). Available from: https:\/\/www.empr.com\/home\/news\/update-regarding-tanzeum-injection-availability\/."},{"issue":"38","key":"10.1016\/j.yjmcc.2025.03.007_bb0605","doi-asserted-by":"crossref","first-page":"35035","DOI":"10.1074\/jbc.M205854200","article-title":"Albumin binding as a general strategy for improving the pharmacokinetics of proteins","volume":"277","author":"Dennis","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.yjmcc.2025.03.007_bb0610","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1210\/jc.2008-1518","article-title":"Pharmacodynamics, pharmacokinetics, safety, and tolerability of Albiglutide, a long-acting glucagon-like Peptide-1 mimetic, in patients with type 2 diabetes","volume":"93","author":"Matthews","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10157","key":"10.1016\/j.yjmcc.2025.03.007_bb0615","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.yjmcc.2025.03.007_bb0620","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s40265-014-0320-7","article-title":"Dulaglutide: First Global Approval","volume":"74","author":"Sanford","year":"2014","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.yjmcc.2025.03.007_bb0625","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1463-1326.2011.01365.x","article-title":"LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects","volume":"13","author":"Barrington","year":"2011","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"10.1016\/j.yjmcc.2025.03.007_bb0630","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/dmrr.1080","article-title":"Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an fc fusion protein","volume":"26","author":"Glaesner","year":"2010","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"10193","key":"10.1016\/j.yjmcc.2025.03.007_bb0635","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.yjmcc.2025.03.007_bb0640","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.2337\/dc22-0903","article-title":"Dulaglutide and a composite outcome reflecting atherosclerosis in the REWIND trial: a post hoc analysis","volume":"45","author":"Ferrannini","year":"2022","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.yjmcc.2025.03.007_bb0645","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/ejhf.2670","article-title":"Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial","volume":"24","author":"Branch","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0650","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am. Heart J."},{"issue":"9","key":"10.1016\/j.yjmcc.2025.03.007_bb0655","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1111\/dom.13361","article-title":"Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"20","author":"Andreadis","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0660","first-page":"61","article-title":"Clinical impact of Semaglutide, a glucagon-like Peptide-1 receptor agonist, on obesity management: a review","volume":"14","author":"Alorfi","year":"2022","journal-title":"Clin. Pharm."},{"issue":"9","key":"10.1016\/j.yjmcc.2025.03.007_bb0665","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31982","article-title":"Weight loss outcomes associated with Semaglutide treatment for patients with overweight or obesity","volume":"5","author":"Ghusn","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0670","series-title":"About the Ozempic (semaglutide) shortage 2022\u20132024 | Therapeutic Goods Administration (TGA) [Internet]","author":"Administration (TGA) TG","year":"2022"},{"issue":"467","key":"10.1016\/j.yjmcc.2025.03.007_bb0675","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0680","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12933-021-01417-0","article-title":"Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients","volume":"20","author":"Saraiva","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0685","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of Liraglutide and Semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front. Endocrinol."},{"issue":"18","key":"10.1016\/j.yjmcc.2025.03.007_bb0690","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like Peptide-1 (GLP-1) analogue Semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.yjmcc.2025.03.007_bb0695","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.yjmcc.2025.03.007_bb0700","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diab. Endocrinol."},{"issue":"19","key":"10.1016\/j.yjmcc.2025.03.007_bb0705","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.yjmcc.2025.03.007_bb0710","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.yjmcc.2025.03.007_bb0715","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diab. Endocrinol."},{"issue":"2","key":"10.1016\/j.yjmcc.2025.03.007_bb0720","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly Semaglutide versus Exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2017","journal-title":"Diab. Care"},{"issue":"5","key":"10.1016\/j.yjmcc.2025.03.007_bb0725","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diab. Endocrinol."},{"issue":"4","key":"10.1016\/j.yjmcc.2025.03.007_bb0730","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diab. Endocrinol."},{"issue":"5","key":"10.1016\/j.yjmcc.2025.03.007_bb0735","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab."},{"issue":"10148","key":"10.1016\/j.yjmcc.2025.03.007_bb0740","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.yjmcc.2025.03.007_bb0745","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/dom.13955","article-title":"Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk","volume":"22","author":"Husain","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"24","key":"10.1016\/j.yjmcc.2025.03.007_bb0750","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0755","series-title":"StatPearls","article-title":"Tirzepatide","author":"Farzam","year":"2023"},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0760","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"issue":"10160","key":"10.1016\/j.yjmcc.2025.03.007_bb0765","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0770","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbrc.2021.09.016","article-title":"Cryo-EM structure of the dual incretin receptor agonist, peptide-19, in complex with the glucagon-like peptide-1 receptor","volume":"578","author":"Johnson","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"13","key":"10.1016\/j.yjmcc.2025.03.007_bb0775","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116506119","article-title":"Structural determinants of dual incretin receptor agonism by tirzepatide","volume":"119","author":"Sun","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"17","key":"10.1016\/j.yjmcc.2025.03.007_bb0780","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.yjmcc.2025.03.007_bb0785","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"10.1016\/j.yjmcc.2025.03.007_bb0790","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.yjmcc.2025.03.007_bb0795","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.yjmcc.2025.03.007_bb0800","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10295","key":"10.1016\/j.yjmcc.2025.03.007_bb0805","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.yjmcc.2025.03.007_bb0810","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10300","key":"10.1016\/j.yjmcc.2025.03.007_bb0815","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"10313","key":"10.1016\/j.yjmcc.2025.03.007_bb0820","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Prato","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.yjmcc.2025.03.007_bb0825","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous Tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.yjmcc.2025.03.007_bb0830","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.yjmcc.2025.03.007_bb0835","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0840","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/oby.23612","article-title":"Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program","volume":"31","author":"le Roux","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0845","unstructured":"Eli Lilly and Company, A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics\/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or Both [Internet]. clinicaltrials.gov; 2023 Oct [cited 2023 Jan 1]. Report No.: NCT05260021. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-003612-31\/IT."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0850","doi-asserted-by":"crossref","first-page":"10","DOI":"10.17925\/EE.2022.18.1.10","article-title":"Tirzepatide: a novel, once-weekly dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes","volume":"18","author":"Kaneko","year":"2022","journal-title":"touchREV Endocrinol."},{"issue":"3","key":"10.1016\/j.yjmcc.2025.03.007_bb0855","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0860","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with Tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.yjmcc.2025.03.007_bb0865","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1001\/jama.2023.24539","article-title":"FDA Green-lights Tirzepatide, marketed as Zepbound, for chronic weight management","volume":"330","author":"Abbasi","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.yjmcc.2025.03.007_bb0870","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.1169","article-title":"Association of Glucagon-like Peptide-1 receptor agonist vs dipeptidyl Peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100502","article-title":"Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection","volume":"14","author":"Michos","year":"2023","journal-title":"Am. J. Prev. Cardiol."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175439","article-title":"Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases","volume":"938","author":"Chen","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.yjmcc.2025.03.007_bb0885","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.03.007_bb0895","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/pharmacy12010011","article-title":"The impact of glucagon-like peptide 1 receptor agonists on obstructive sleep Apnoea: a scoping review","volume":"12","author":"Le","year":"2024","journal-title":"Pharmacy"},{"issue":"4","key":"10.1016\/j.yjmcc.2025.03.007_bb0900","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0905","doi-asserted-by":"crossref","first-page":"102006","DOI":"10.1016\/j.molmet.2024.102006","article-title":"AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys","volume":"88","author":"Jensen","year":"2024","journal-title":"Mol. Metab."},{"issue":"2","key":"10.1016\/j.yjmcc.2025.03.007_bb0910","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nat. Metab."},{"issue":"4","key":"10.1016\/j.yjmcc.2025.03.007_bb0915","doi-asserted-by":"crossref","first-page":"E835","DOI":"10.1152\/ajpendo.00646.2020","article-title":"GIP receptor deletion in mice confers resistance to high-fat diet-induced obesity via alterations in energy expenditure and adipose tissue lipid metabolism","volume":"320","author":"Boer","year":"2021","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.yjmcc.2025.03.007_bb0920","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.mce.2015.07.001","article-title":"Internalization and desensitization of the human glucose-dependent-insulinotropic receptor is affected by N-terminal acetylation of the agonist","volume":"414","author":"Ismail","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"issue":"8","key":"10.1016\/j.yjmcc.2025.03.007_bb0925","doi-asserted-by":"crossref","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.yjmcc.2025.03.007_bb0930","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1074\/jbc.M114.592436","article-title":"Functional consequences of glucagon-like Peptide-1 receptor cross-talk and trafficking","volume":"290","author":"Roed","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.yjmcc.2025.03.007_bb0935","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1124\/mol.111.074757","article-title":"Lateral Allosterism in the glucagon receptor family: glucagon-like peptide 1 induces G-protein-coupled receptor Heteromer formation","volume":"81","author":"Schelshorn","year":"2012","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.yjmcc.2025.03.007_bb0940","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacbts.2018.11.001","article-title":"Glucagon receptor antagonism ameliorates progression of heart failure","volume":"4","author":"Gao","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"issue":"5","key":"10.1016\/j.yjmcc.2025.03.007_bb0945","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/CIRCRESAHA.124.324706","article-title":"Glucagon receptor antagonist for heart failure with preserved ejection fraction","volume":"135","author":"Gao","year":"2024","journal-title":"Circ. Res."}],"container-title":["Journal of Molecular and Cellular Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282825000471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282825000471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:56:29Z","timestamp":1777694189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022282825000471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":189,"alternative-id":["S0022282825000471"],"URL":"https:\/\/doi.org\/10.1016\/j.yjmcc.2025.03.007","relation":{},"ISSN":["0022-2828"],"issn-type":[{"value":"0022-2828","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in incretin therapies for targeting cardiovascular disease in diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yjmcc.2025.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}